• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Radiation Delay in NSCLC May Aid Outcomes, But Raises Toxicity Risks

by MM360 Staff | Apr 18, 2025 | Uncategorized

Source: CureToday articles Deferring upfront CNS-directed radiation in EGFR-variant and ALK-positive NSCLC may improve outcomes but raises treatment-related toxicity risks. Read More

CAR-T for multiple myeloma: practice pearls

by MM360 Staff | Apr 18, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience

by MM360 Staff | Apr 18, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Compounding Confidence: Navigating Challenges With Innovative Technology in Pharmacy

by MM360 Staff | Apr 17, 2025 | Myeloma News

Source: Pharmacy Times articles Hospital compounding is gaining renewed attention amid drug shortages, regulatory changes, and labor challenges, prompting pharmacies to leverage advanced technology for safer, more efficient, and compliant medication preparation. Read...

Radiation Therapy Now More Targeted and Tolerable in GI Cancer

by MM360 Staff | Apr 17, 2025 | Uncategorized

Source: CureToday articles Radiation therapy for gastrointestinal cancers is more precise and easier to tolerate due newer technologies and personalized care, according to experts. Read More
« Older Entries
Next Entries »

Recent Content

  • Renowned Breast Cancer Physician-Scientist Dr. Hope S. Rugo to Lead City of Hope’s Women’s Cancers Program
  • Measles Cases Climb to 800 in United States as Outbreak Spreads Across Borders
  • Reassessing Immunotherapy Use in Advanced Renal Cell Carcinoma
  • SPPCP 2025: Highlights and Can’t-Miss Sessions From the Virtual Conference on Pain and Palliative Care Pharmacy
  • First-Line Focus: Molecular Testing and Guideline-Directed Therapy in EGFR-Positive NSCLC
  • Momelotinib Shows Strong Efficacy in JAK-Exposed Myelofibrosis Patients
  • Recognizing Symptoms During Head and Neck Cancer Awareness Month
  • Overcoming Challenges in NSCLC Management From a Pharmacist’s Perspective
  • AI Tool May Better Predict Transplant Risk in Myelofibrosis
  • Study: Vision Impairment Signals Linked to Semaglutide Use
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT